1d
Pacira BioSciences: Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences ...
Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three ...
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...
The company emphasized its patent protection for the EXPAREL franchise, which extends until January 2041, with the IVRA family approved in 2024 having exclusivity until July 2044. Despite the positive ...
BRISBANE, Calif. - Pacira BioSciences, Inc. (NASDAQ:PCRX), a pharmaceutical company with annual revenues of $705.85 million and a robust gross profit margin of 66.51%, announced Monday it has received ...
BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...
(MENAFN- GlobeNewsWire - Nasdaq) -- Findings Presented at AMCP Nexus 2025 Annual Meeting -- BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback